You are here

Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate

Last updated on November 19, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Kalamazoo, Michigan, 49007 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Healthy
Sex
Male
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-55 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- BMI 17.5 to 30.5 kg/m2 and total body weight >50 kg

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Fasting glucose above the limits of the reference range for healthy individuals

- "No treatment" OGTT indicative of impaired fasting glucose or impaired glucose
tolerance

- Severe acute or chronic medical or psychiatric condition or laboratory abnormality
that may increase the risk associated with study participation

NCT01199029
Pfizer
Completed
Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate
Official Title  ICMJE An Open Label Study Evaluating The Effect Of Single Doses Of Pf-04308515 And Prednisone On Carbohydrate Metabolism Utilizing An Oral Glucose Tolerance Test In Healthy Adult Subjects
Brief SummaryThis study will investigate the effect of a single dose of PF-04308515 or prednisone on calculated measures of glucose tolerance and insulin resistance by using a modified oral glucose tolerance test.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Healthy
Intervention  ICMJE
  • Drug: PF-04308515
    10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)
  • Drug: PF-04308515
    10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)
  • Drug: Prednisone
    5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
  • Drug: PF-04308515
    X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
  • Drug: PF-04308515
    Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
  • Drug: Prednisone
    20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
Study Arms  ICMJE
  • Experimental: (Part 1) 10 mg PF-04308515 (8hrs)
    Intervention: Drug: PF-04308515
  • Experimental: (Part 1) 10 mg PF-04308515 (12hrs)
    Intervention: Drug: PF-04308515
  • Active Comparator: (Part 1) 5 mg Prednisone
    Intervention: Drug: Prednisone
  • Experimental: (Part 2) X mg PF-04308515
    Intervention: Drug: PF-04308515
  • Experimental: (Part 2) Y mg PF-04308515
    Intervention: Drug: PF-04308515
  • Active Comparator: (Part 2) 5 mg Prednisone
    Intervention: Drug: Prednisone
  • Active Comparator: (Part 2) 20 mg Prednisone
    Intervention: Drug: Prednisone
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 15, 2010)
18
Original Estimated Enrollment  ICMJE
 (submitted: September 9, 2010)
34
Actual Study Completion Date  ICMJE September 2010
Actual Primary Completion DateSeptember 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • BMI 17.5 to 30.5 kg/m2 and total body weight >50 kg

Exclusion Criteria:

  • Fasting glucose above the limits of the reference range for healthy individuals
  • "No treatment" OGTT indicative of impaired fasting glucose or impaired glucose tolerance
  • Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation
Sex/Gender  ICMJE
Sexes Eligible for Study:Male
Ages  ICMJE 18 Years to 55 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01199029
Other Study ID Numbers  ICMJE B0861004
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyDirector, Clinical Trial Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateDecember 2010

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now